{
    "clinical_study": {
        "@rank": "88969", 
        "arm_group": {
            "arm_group_label": "Daily PrEP + coordination of client centered svs", 
            "arm_group_type": "Other", 
            "description": "All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4."
        }, 
        "brief_summary": {
            "textblock": "Black men who have sex with men (MSM) Pre-Exposure Prophylaxis (PrEP) Study with Client\n      Centered Care Coordination (C4)Component."
        }, 
        "brief_title": "HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)", 
        "condition": "HIV", 
        "detailed_description": {
            "textblock": "An open label demonstration study with PrEP and Client Centered Care Coordination (C4) to\n      assess the initiation, acceptability, safety, and feasibility of PrEP for Black MSM (BMSM)\n      in three US Cities.  A subset of participants will also be recruited to participate in\n      qualitative interviews about facilitators and barriers regarding PrEP.  The study will\n      recruit HIV-uninfected BMSM at risk for HIV infection in three US Cities.  Enrollment will\n      include those aged 18 and over with an effort to recruit an equal number of BMSM under age\n      25 and over age 25 with a total of 225 participants (75 per site)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        BMSM who meet all of the following criteria are eligible for inclusion in this study:\n\n          -  18 years of age or older\n\n          -  No prior HIV diagnosis (self-report)\n\n          -  Male at birth\n\n          -  High risk for acquiring HIV infection including any one of the following in the\n             previous 6 months:\n\n               -  Unprotected sex during receptive or insertive anal intercourse with a male\n                  partner\n\n               -  Any protected or unprotected:\n\n                  i. Receptive or insertive anal intercourse with more than three male sex\n                  partners ii. Exchange of money, gifts, shelter or drugs for receptive or\n                  insertive anal sex with a male partner iii. Receptive or insertive anal sex\n                  while under the influence of drugs or alcohol (i.e., high or drunk within two\n                  hours of the sex act) according to self-report\"\n\n               -  STI diagnosis (i.e., syphilis, gonorrhea and chlamydia) by self-report\n\n          -  Willing to provide locator information in accordance with the Study Specific\n             Procedures (SSP) Manual\n\n          -  Urine dipstick negative or trace for protein and glucose\n\n          -  Hemoglobin > 11 g/dL, absolute neutrophil count > 750 cells/mm3, and platelet count \u2265\n             100,000/mm3\n\n          -  Serum creatinine < upper limit of normal (ULN) and calculated creatinine clearance of\n             at least 60 mL/min by the Cockcroft-Gault formula where:\n\n             o eCcr in mL/min =  [(140 - age in years) x (actual body weight in kg)] / (72 x serum\n             creatinine in mg/dL) Alanine aminotransferase (AST) and aspartate aminotransferase\n             (ALT) < 3 times the upper limit of normal (ULN)\n\n          -  Total bilirubin < 2.5 ULN\n\n          -  Hepatitis B surface antigen (HBsAg) negative\n\n        Exclusion Criteria:\n\n        BMSM who meet any of the following criteria will be excluded from this study:\n\n          -  Any reactive or positive HIV test at Screening, even if subsequent testing indicates\n             that the person is HIV-uninfected\n\n          -  Transgender\n\n          -  Active or chronic hepatitis B infection (as evidenced by HBsAg, HbsAb, and HbcAb\n             testing)\n\n          -  Planning to move out of the area or to travel for more than 3 months during the study\n             follow-up period\n\n          -  Unwilling to adhere to study procedures\n\n          -  Current participation in any research study via self-report (however, strictly\n             non-HIV centered observational studies are not exclusionary)\n\n          -  Previous participation in an HIV vaccine study is exclusionary unless documented\n             evidence of enrollment into a placebo arm\n\n          -  Use of ARV drugs (PrEP or PEP) in the last 60 days\n\n          -  Prior history of a gastrectomy, colostomy, ileostomy, or any other procedure altering\n             the gastrointestinal tract or drug absorption (provided by self-report, or obtained\n             from medical history or records)\n\n          -  Receipt of prohibited medications: interleukin therapy, medications with significant\n             nephrotoxic potential (including but not limited to amphotericin B, aminoglycosides,\n             cidofovir, foscarnet and systemic chemotherapy), and medications that may inhibit or\n             compete for elimination via active renal tubular secretion (including but not limited\n             to probenecid) - (provided by self-report, or obtained from medical history or\n             medical records)\n\n          -  Any condition, that in the opinion of study staff, would make participation in the\n             study unsafe, or interfere with achieving the study objective"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "225", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808352", 
            "org_study_id": "HPTN 073"
        }, 
        "intervention": {
            "arm_group_label": "Daily PrEP + coordination of client centered svs", 
            "description": "All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.", 
            "intervention_name": "FTC/TDF", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tenofovir disoproxil", 
                "Tenofovir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "AE     adverse event", 
            "AIDS     acquired immunodeficiency syndrome", 
            "ALT (SGPT)    alanine aminotransferase", 
            "ART    antiretroviral therapy", 
            "AST (SGOT)    aspartate aminotransferase", 
            "DCF    data collection forms", 
            "DMC     Data Monitoring Committee", 
            "FDA     (U.S.) Food and Drug Administration", 
            "GCP     Good Clinical Practice guidelines", 
            "HB sAg    Hepatitis B surface antigen", 
            "ICH     International Conference of Harmonisation", 
            "IND    Investigational New Drug Application", 
            "IRB     Institutional Review Board", 
            "IU     International units", 
            "mg     milligram(s)", 
            "mm3     cubic millimeter(s)", 
            "PCR     polymerase chain reaction", 
            "SAE     serious adverse event", 
            "\u00b5g      microgram", 
            "ULN     upper limit of the normal range", 
            "WB     Western Blot"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sshoptaw@mednet.ucla.edu", 
                    "last_name": "Steven Shoptaw, PhD", 
                    "phone": "310-794-6206"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "UCLA Vine Street Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "manyadm@gwu.edu", 
                    "last_name": "Manya Magnus, PhD, MPH", 
                    "phone": "202-994-3024"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }, 
                    "name": "George Washington University CRS"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lisa_hightow@med.unc.edu", 
                    "last_name": "Lisa Hightow-Weidman", 
                    "phone": "919-843-0033"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "UNC CRS"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities", 
        "overall_official": [
            {
                "affiliation": "UCLA Vice Street Clinic", 
                "last_name": "Steven Shoptaw, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "George Washington University CRS", 
                "last_name": "Manya Magnus, PhD, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "UNC CRS", 
                "last_name": "Lisa Hightow-Weidman", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Documented in either study CRFs or ACASI", 
                "measure": "Initiation of PrEP", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Adherence will be assessed via self-report (ACASI), PBMCs and plasma concentration", 
                "measure": "Adherence to PrEP", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808352"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Graded via DAIDS Toxicity Grading System determined by review of reported adverse events (clinical and laboratory)", 
                "measure": "Adverse events", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Rectal and urine GC/CT, and NAAT for syphilis and chlamydia", 
                "measure": "STIs", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Measured by ACASI assessments", 
                "measure": "Changes in sexual risk-taking behavior", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Refusal rates will be measured by ACASI assessments", 
                "measure": "Initiate or decline PrEP", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "HIV RNA and genotyping will be performed at the NL on samples confirmed to be HIV infected", 
                "measure": "Incident HIV-seroconversions/characteristics", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assessed via interviewer-administered questionnaire", 
                "measure": "Participant perception of care and referral plan", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }
        ], 
        "source": "HIV Prevention Trials Network", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HIV Prevention Trials Network", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}